These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 11884499

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.
    Liu G, He J, Dou S, Gupta S, Vanderheyden JL, Rusckowski M, Hnatowich DJ.
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):417-24. PubMed ID: 14691611
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predicting the biodistribution of radiolabeled cMORF effector in MORF-pretargeted mice.
    Liu G, Dou S, He J, Liu X, Rusckowski M, Hnatowich DJ.
    Eur J Nucl Med Mol Imaging; 2007 Feb; 34(2):237-46. PubMed ID: 17021815
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The influence of chain length and base sequence on the pharmacokinetic behavior of 99mTc-morpholinos in mice.
    Liu G, Zhang S, He J, Liu N, Gupta S, Rusckowski M, Hnatowich DJ.
    Q J Nucl Med; 2002 Sep; 46(3):233-43. PubMed ID: 12134139
    [Abstract] [Full Text] [Related]

  • 9. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector.
    Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, Hnatowich DJ.
    Q J Nucl Med Mol Imaging; 2010 Jun; 54(3):333-40. PubMed ID: 20639818
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Successful radiotherapy of tumor in pretargeted mice by 188Re-radiolabeled phosphorodiamidate morpholino oligomer, a synthetic DNA analogue.
    Liu G, Dou S, Mardirossian G, He J, Zhang S, Liu X, Rusckowski M, Hnatowich DJ.
    Clin Cancer Res; 2006 Aug 15; 12(16):4958-64. PubMed ID: 16914585
    [Abstract] [Full Text] [Related]

  • 17. Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORF.
    Liu G, Dou S, Pretorius PH, Liu X, Rusckowski M, Hnatowich DJ.
    Eur J Nucl Med Mol Imaging; 2008 Feb 15; 35(2):272-80. PubMed ID: 17909792
    [Abstract] [Full Text] [Related]

  • 18. 90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.
    Liu G, Dou S, Liu Y, Wang Y, Rusckowski M, Hnatowich DJ.
    Bioconjug Chem; 2011 Dec 21; 22(12):2539-45. PubMed ID: 21985267
    [Abstract] [Full Text] [Related]

  • 19. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
    Yao Z, Zhang M, Axworthy DB, Wong KJ, Garmestani K, Park L, Park CW, Mallett RW, Theodore LJ, Yau EK, Waldmann TA, Brechbiel MW, Paik CH, Pastan I, Carrasquillo JA.
    Cancer Res; 2002 Oct 15; 62(20):5755-60. PubMed ID: 12384535
    [Abstract] [Full Text] [Related]

  • 20. Optimizing bispecific antibody pretargeting for use in radioimmunotherapy.
    Sharkey RM, Karacay H, Richel H, McBride WJ, Rossi EA, Chang K, Yeldell D, Griffiths GL, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3897S-913S. PubMed ID: 14506188
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.